How to buy Viridian Therapeutics stock (VRDN)

Viridian Therapeutics is a biotechnology business based in the US. Viridian Therapeutics shares (VRDN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $18.73 – an increase of 4.93% over the previous week. Viridian Therapeutics employs 94 staff and has a trailing 12-month revenue of around $302,000.

Our top picks for where to buy Viridian Therapeutics stock

Buy Viridian Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Viridian Therapeutics stock price (NASDAQ: VRDN)

Use our graph to track the performance of VRDN stocks over time.

Viridian Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$18.73
52-week range	$11.40 - $27.20
50-day moving average more info button	$21.98
200-day moving average more info button	$17.30
Wall St. target price	$41.06
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-4.32

Is it a good time to buy Viridian Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Viridian Therapeutics price performance over time

Historical closes compared with the close of $20.82 from 2024-12-17

1 week (2024-12-13)	16.64%
1 month (2024-11-20)	5.20%
3 months (2024-09-20)	-6.64%
6 months (2024-06-20)	68.17%

1 year (2023-12-20)	1.91%
2 years (2022-12-20)	-24.35%
3 years (2021-12-20)	4.62%
5 years (2019-12-20)	201.74%

Viridian Therapeutics financials

Revenue TTM	$302,000
Gross profit TTM	$-99,122,000
Return on assets TTM	-32.15%
Return on equity TTM	-51.88%
Profit margin	0%
Book value	$6.55
Market Capitalization more info button	$1.5 billion

TTM: trailing 12 months

Viridian Therapeutics share dividends

We're not expecting Viridian Therapeutics to pay a dividend over the next 12 months.

Have Viridian Therapeutics's shares ever split?

Viridian Therapeutics's shares were split on a 1:15 basis on 12 November 2020 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Viridian Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Viridian Therapeutics shares which in turn could have impacted Viridian Therapeutics's share price.

Viridian Therapeutics share price volatility

Over the last 12 months, Viridian Therapeutics's shares have ranged in value from as little as $11.4 up to $27.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viridian Therapeutics's is 1.114. This would suggest that Viridian Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Viridian Therapeutics overview

Viridian Therapeutics, Inc. , a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc.

Frequently asked questions

What percentage of Viridian Therapeutics is owned by insiders or institutions?
Currently 0.006% of Viridian Therapeutics shares are held by insiders and 112.359% by institutions. How many people work for Viridian Therapeutics?
Latest data suggests 94 work at Viridian Therapeutics. When does the fiscal year end for Viridian Therapeutics?
Viridian Therapeutics's fiscal year ends in December. Where is Viridian Therapeutics based?
Viridian Therapeutics's address is: 221 Crescent Street, Waltham, MA, United States, 02453 What is Viridian Therapeutics's ISIN number?
Viridian Therapeutics's international securities identification number is: US92790C1045